阿西米尼对比博舒替尼治疗既往接受过至少两种酪氨酸激酶抑制剂治疗的慢性期慢性髓性白血病:ASCEMBL研究长期随访
ASCEMBL研究纳入既往接受≥2种酪氨酸激酶抑制剂(TKI)治疗的慢性期慢性髓性白血病(CML-CP)患者,随机2:1接受阿西米尼40 mg每日两次或博舒替尼500 mg每日一次。中位随访2.3年,阿西米尼第96周主要分子学反应(MMR)率37.6% vs 博舒替尼15.8%,校正基线主要细胞遗传学反应(MCyR)后MMR率差异21.7%(95%CI 10.53-32.95;双侧p=0.001),≥3级不良事件(AE)及导致治疗中断的AE均更少。
要点
- 阿西米尼第96周MMR率37.6%,博舒替尼15.8%,校正后差异21.7%(95%CI 10.53-32.95;p=0.001)。
- 阿西米尼≥3级AE发生率56.4%,博舒替尼68.4%;导致治疗中断的AE分别为7.7%和26.3%。
- 阿西米尼组继续接受治疗并从随时间获益的患者比例高于博舒替尼组。
核心结论
- 中位随访2.3年后,阿西米尼对比博舒替尼在既往接受≥2种TKI治疗的CML-CP患者中持续显示更优疗效及更好的安全性和耐受性,支持阿西米尼作为该类患者的标准治疗。
研究设计与样本
- ASCEMBL研究为随机、 stratified by baseline MCyR、2:1分配的临床试验,纳入既往接受≥2种TKI治疗的CML-CP患者,分别接受阿西米尼40 mg每日两次或博舒替尼500 mg每日一次。
- 中位随访2.3年,报告第96周关键次要终点MMR率及安全性数据。
主要发现
- 第96周MMR率阿西米尼组37.6% vs 博舒替尼组15.8%;校正基线MCyR后组间MMR率差异21.7%(95%CI 10.53-32.95;双侧p=0.001)。
- ≥3级AE发生率阿西米尼组56.4% vs 博舒替尼组68.4%;导致治疗中断的AE发生率阿西米尼组7.7% vs 博舒替尼组26.3%。
- 阿西米尼组继续接受治疗并从随时间获益的患者比例高于博舒替尼组。
关键数值与推荐
- 第96周MMR率:阿西米尼组37.6% vs 博舒替尼组15.8%,校正基线MCyR后差异21.7%(95%CI 10.53-32.95;双侧p=0.001)。
- ≥3级AE发生率:阿西米尼组56.4% vs 博舒替尼组68.4%。
- 导致治疗中断的AE发生率:阿西米尼组7.7% vs 博舒替尼组26.3%。
临床怎么用
- 原文结论支持阿西米尼作为既往接受≥2种TKI治疗的CML-CP患者的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) treated with ≥2 prior tyrosine kinase inhibitors (TKIs). In ASCEMBL, patients with CML-CP treated with ≥2 prior TKIs were randomized (stratified by baseline major cytogenetic response [MCyR]) 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily. Consistent with previously published primary analysis results, after a median follow-up of 2.3 years, asciminib continued to demonstrate superior efficacy and better safety and tolerability than bosutinib. The major molecular response (MMR) rate at week 96 (key secondary endpoint) was 37.6% with asciminib vs 15.8% with bosutinib; the MMR rate difference between the arms, after adjusting for baseline MCyR, was 21.7% (95% CI, 10.53-32.95; two-sided p = 0.001). Fewer grade ≥3 adverse events (AEs) (56.4% vs 68.4%) and AEs leading to treatment discontinuation (7.7% vs 26.3%) occurred with asciminib than with bosutinib. A higher proportion of patients on asciminib than bosutinib remained on treatment and continued to derive benefit over time, supporting asciminib as a standard of care for patients with CML-CP previously treated with ≥2 TKIs.
引用
- Hochhaus A, Réa D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023. PMID: 36717654. doi:10.1038/s41375-023-01829-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。